Canbridge Pharmaceuticals
在场
Canbridge Pharmaceuticals 是一家在股票代码 1228 (CN) 下上市的公司。
高管
查看带有其 26 名主要高管的组织结构图
Canbridge Pharmaceuticals 搜索最多的简介
- James Xue, Chairman of the Board and Chief Executive Officer
- Lan Hu, Independent Director
- Peng Kuan Chan, Independent Non-Executive Director
创建提醒
跟踪 Canbridge Pharmaceuticals 的高管变动
药店
Canbridge Pharmaceuticals 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
药店 行业的其他推荐联系人
消息
Canbridge Pharmaceuticals 的最新新闻稿
- CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies
- CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration
- CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
- CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA
- CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
- CANbridge’s Livmarli Is Recommended in The “ Expert Consensus on Diagnosis and Treatment of ALGS Associated Liver Disease” Published By The Chinese Journal of Pediatrics
- CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease
- CANbridge Announces Expansion of LIVMARLI® Label to Include Patients as Young as 3 Months in China
- CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023
- CANbridge and PUMCH announced the establishment of PUMCH- CANbridge Genetic Defect Rare Disease Innovation and Translation Base
- View more press releases Close
通过电子邮件
